BioNexus Gene Lab Corp.
BGLC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 12.5% | 5.8% | -15.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 14.8% | 16.3% | 16.1% | 12.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -26.2% | -25.2% | -25.6% | -14.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -27.9% | -27.3% | -29.2% | -13.8% |
| EPS Diluted | -0.39 | -0.34 | -0.35 | -0.19 |
| % Growth | -14.7% | 2.9% | -84.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |